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Cytokine gene polymorphisms in hemodialysis patients: Asso-
ciation with comorbidity, functionality, and serum albumin.
Background. Cytokine-orchestrated chronic inflammation
plays a major role in long-term morbidity and mortality in pa-
tients with end-stage renal disease (ESRD) on hemodialysis
(HD). In this cross-sectional study, we evaluated the associ-
ation between specific alleles/genotypes and combinations of
genotypes of interleukin (IL)-6, tumor necrosis factor-a (TNF-
a), and IL-10 with indices of comorbidity, functional status, and
other biological markers in a cohort of 183 ESRD patients re-
cruited to the Hemodialysis (HEMO) Study from two Boston
centers.
Methods. Genotyping was performed for single nucleotide
polymorphisms in the promoter region of IL-6 (–174 G→C),
TNF-a (–308 G→A), and IL-10 (−1082 G→A). The re-
lationship of specific genotypes to the index of coexistent
disease (ICED) score (an index of comorbidity), Karnof-
sky Index (a measure of functional status), serum albumin,
and nutritional indices (anthropometric measurements, body
mass index, normalized protein catabolic ratio) were studied.
Plasma IL-6 levels, as well as TNF-a and IL-10 production
by endotoxin-stimulated peripheral blood mononuclear cells
(PBMC), were also measured by enzyme-linked immunosor-
bent assay (ELISA).
Results. Patients with the high producer genotypes for the
proinflammatory cytokines IL-6 (G/G and G/C) and TNF-a
(G/A and A/A) had significantly higher comorbidity (ICED
scores of ≥2) and lower functional scores (Karnofsky Index)
compared with patients with the low producer genotypes for
these cytokines (C/C and G/G, respectively). In contrast, pa-
tients with the high and intermediate producer genotypes (G/G
and G/A) for the anti-inflammatory cytokine IL-10 had a higher
Karnofsky Index compared with those with the low producer
genotype (A/A). Serum albumin levels were lower in patients
with the TNF-a high producer genotype (G/A and A/A) com-
pared with those with the low producer genotype (G/A and
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A/A). On multivariate analysis, the IL-6 high producer geno-
types were associated with an odds ratio (OR) of 4.87 for
higher comorbidity (ICED scores ≥2) (P = 0.02), and 4.9 for
lower Karnofsky Index (lower functional status) (P = 0.04)
compared with patients with the low IL-6 producer genotypes.
Similarly, the TNF-a high producer genotype was associated
with increased odds for a higher ICED score, lower Karnof-
sky Index, and lower serum albumin compared with patients
with the low producer genotype for this cytokine. In contrast,
the IL-10 high/intermediate producer genotype was associated
with increased odds for a higher Karnofsky Index (P = 0.05).
Cytokine genotype combinations—the TNF-a high producer
and IL-6 high producer genotype combination, and the IL-6
high producer and IL-10 low producer genotype combination—
were independently associated with a higher ICED score. These
genotype combinations, as well as the TNF-a high producer and
IL-10 low producer genotype combination, were also associated
with a lower Karnofsky Index.
Conclusion. In ESRD patients on long-term HD, single nu-
cleotide polymorphisms in the promoter region of the proin-
flammatory cytokines IL-6 and TNF-a, and the regulatory
monokine IL-10, show a strong association with indices of co-
morbidity and function, and biological and nutritional markers.
In recent years, several studies have shown a strong as-
sociation between chronic inflammation and long-term
morbidity and mortality in patients with end-stage renal
disease (ESRD) on hemodialysis (HD) [1]. Proinflam-
matory cytokines such as interleukin-6 (IL-6) and tumor
necrosis factor-a (TNF-a) are believed to be key orches-
trators of this inflammatory response. These cytokines
have been implicated as key factors that link malnutri-
tion, accelerated atherogenesis, and excessive morbidity
and mortality in ESRD patients on HD [2]. In addition
to proinflammatory cytokines, inflammatory stimuli also
lead to the expression and release of anti-inflammatory
cytokines, particularly interleukin-10 (IL-10). Previous
studies have shown that IL-10, released by endotoxin-
stimulated monocytes, inhibits production of IL-1b ,
TNF-a, and IL-6 [3]. As its expression is relatively de-
layed, release of IL-10 provides an efficient autocrine
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mechanism for regulating proinflammatory cytokine pro-
duction [4]. However, recent studies have shown that
there is considerable interindividual variation in the max-
imal capacity to produce different cytokines in response
to mitogen stimulation in vitro [5]. Furthermore, overall
expression and production of cytokines is, in part, ge-
netically determined. Stable allelic variants for several
cytokine genes, arising from nucleotide polymorphisms
within the regulatory region, have been described in re-
cent years. Polymorphisms involving the 5′-flanking re-
gion (promoter) of the TNF-a, IL-6, and IL-10 genes
affecting transcriptional activity and, therefore, of func-
tional relevance have been identified [6].
In this study, we determined the relative frequency of
specific alleles/genotypes of IL-6, TNF-a, and IL-10 in
a cohort of 183 patients with ESRD on HD, and eval-
uated the relationship of specific alleles/genotypes and
combinations of genotypes to indices of comorbidity and
functional status, and biological and nutritional markers.
METHODS
Subjects
The study cohort consisted of 217 patients with ESRD
on maintenance HD recruited to the baseline phase of
the Hemodialysis (HEMO) Study from two Boston cen-
ters. The HEMO Study was sponsored by the United
States National Institute of Diabetes, Digestive, and Kid-
ney Diseases, and the full-scale trial began in 1995. De-
tails regarding the design of the HEMO Study have been
published elsewhere [7]. In brief, this was a multicenter,
prospective, randomized clinical trial designed to evalu-
ate the effect of dialyzer urea and b2-microglobulin clear-
ances on the morbidity and mortality of patients. Patients
were eligible for inclusion into the HEMO Study if they
were between the ages of 18 and 80 years, had been re-
ceiving chronic HD three times per week, and had resid-
ual renal clearance of urea of less than 1.5 mL/min/35
L of urea distribution volume. Those patients in acute or
chronic care hospitals, with active malignancy, decompen-
sated cardiac, hepatic, or pulmonary disease, serum albu-
min <2.6 g/dL, interdialytic urea clearance >1.5 mL/min,
pregnancy, or a scheduled or recently (<6 months) failed
transplant were excluded.
Blood samples for genotyping were available for 187
patients. Of these, 102 patients were Caucasian and 81
were African American. As there were only four patients
representing other races, analysis was confined to these
183 patients. Randomization to either a standard or high
dose of dialysis, and to either a low- or high-flux dialyzer
was carried out in 175 patients in whom outcomes on
follow-up were studied.
This ancillary study was approved by the Human Inves-
tigation Review Committee (HIRC), and all participants
provided written, informed consent.
Table 1. ICED and Karnofsky Index scoring system
Proportion
in cohort
Level Status (No., %)
ICED
0 No comorbidity –
1 Asymptomatic to mildly symptomatic 60 (34)
2 Moderate symptoms, require medications 58 (33)
for control of disease
3 Severe symptoms, inadequate control of 60 (33)
disease despite maximal medical therapy
Karnofsky Index
100 Normal 32 (15)
90 Normal activity; minor symptoms/signs 73 (34)
of disease
80 Normal activity with effort 42 (20)
70 Cares for self 20 (9)
60 Self-care with minimal help 18 (8)
50 Self-care with considerable help 15 (7)
40 Disabled; needs special care 13 (6)
30 Severely disabled –
20 Very sick; hospitalization needed –
10 Moribund –
Data procurement
Demographic, medical, and socioeconomic informa-
tion was obtained once patients were enrolled into the
baseline phase of the study. During the fifth week of
the study, while the patients were still in the baseline
phase, their comorbid medical conditions were assessed
and recorded on a standardized form. The form was com-
pleted at each clinical center by specially trained study
coordinators. The information available for completion
of the form included chart progress notes, list of current
medications, and the most recent laboratory data, chest
x-ray report, electrocardiogram, and hospital discharge
summary, and was supplemented by interviews of the pa-
tients, family members, primary nephrologists, and dial-
ysis staff as necessary.
The comorbidities were cataloged using the Index of
CoExisting Diseases (ICED), a coding system that classi-
fies the presence and severity of 19 different diseases and
11 physical impairments [8]. Disease severity was scored
on a scale from 0 to 3, with 0 indicating the absence of
disease, and increasing values indicating increasing sever-
ity of the disease. The highest scores of Index of Disease
Severity (IDS) and Index of Physical Impairment (IPI)
were combined to create the ICED score, from 0 to 3
(Table 1). Functional status was assessed by means of the
Karnofsky Index (KI) [9]. The KI is an overall indicator
of the patient’s level of physical functioning and is used
frequently in clinical research. KI scores range from 10
(lowest level) to 100 (highest level) (Table 1). Clinical
assessment of nutritional status included anthropometric
measurements and body mass index.
The primary outcome defined in the HEMO Study was
death from any cause. Three secondary outcomes were
included: one a composite of death from any cause and
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the first decline of >15% from baseline in serum albu-
min, and the second, a composite of first cardiac hos-
pitalization and cardiac death. The third, cardiovascular
death, referred to deaths caused by ischemic heart disease
(IHD), congestive heart failure (CHF), arrhythmias, or
other heart disease, or cerebrovascular disease.
Blood samples were obtained predialysis, as part of
the routine clinical protocol, within one month of en-
rollment for measurement of routine laboratory pa-
rameters [including predialysis and postdialysis urea for
calculation of dialysis dose (Kt/V) and normalized pro-
tein catabolic rate (nPCR)]. Equilibrated postdialysis
urea from the rate equation of Daugirdas and Schneditz
was used for calculation of Kt/V and nPCR [10]. A 30-mL
heparinized blood sample was also collected as part of an
ancillary study investigating the role of dialyzer flux and
dialysis dose on cytokine production by peripheral blood
mononuclear cells (PBMC). Plasma samples were stored
at –80◦C until IL-6 measurements and isolated PBMC
aliquots were utilized for DNA extraction and genotyp-
ing, as well as endotoxin-stimulated cytokine production.
PBMC isolation and DNA extraction
PBMC were harvested as previously described from
whole blood, using Ficoll-Hypaque density gradient sepa-
ration technique [11]. Cell aliquots (2.5 × 106 PBMC/mL)
were resuspended in RPMI 1640 cell culture medium
supplemented with L-glutamine, NaHCO3, HEPES, peni-
cillin, and streptomycin, and stored at –80◦C until DNA
extraction.
Genomic DNA was extracted using a spin column
method (QIAamp DNA Mini Kit; Qiagen, Valencia, CA,
USA). In brief, 2.5 × 106 PBMC were treated with 20 lL
of proteinase K (Qiagen), followed by the addition of
200 lL of sodium dodecyl sulfate (SDS) to lyse the cells.
The homogeneous solution was incubated at 56◦C for 10
minutes, and 200 lL of 100% ethanol was added to pre-
cipitate DNA. The mixture was then applied to the QI-
Aamp spin column, and after two washes with 500 lL of
wash buffer, genomic DNA was eluted by the addition of
200 lL of elution buffer. Final DNA concentrations were
50 to 200 ng/mL determined by minigel electrophoresis.
Cytokine promoter genotyping
Polymerase chain reaction (PCR)-sequence-specific
primer (SSP) approach was used to analyze one to three
single nucleotide allelic variations in the promoter re-
gions of IL-6, TNF-a, and IL-10. Polymorphic alleles
at –174 (G→C), –308 (G→A), and –1082 (G→A) of
the IL-6, TNF-a, and IL-10 promoter regions, respec-
tively, were studied. PCR was performed on the purified
DNA using a Cytokine Genotyping Tray (One Lambda,
Inc., Canoga Park, CA, USA), which provided sequence-
specific oligonucleotide primers for the three cytokines.
It is based on the principle that completely matched
oligonucleotide primers are more efficiently used in am-
plifying a target sequence than a mismatched oligonu-
cleotide primer by recombinant Taq polymerase. Primer
pairs are designed to have perfect matches only with a
single allele or group of alleles. Under strictly controlled
PCR conditions, perfectly matched primer pairs result in
amplification of target sequences (i.e., a positive result),
while mismatched primer pairs do not result in amplifi-
cation (i.e., a negative result). In brief, 20 lL of genomic
DNA solution was added to the D-mix, which contains
the desoxynucleoside triphosphate (dNTPs) and reac-
tion buffer, for the cytokine genotyping. Taq polymerase
(1.1 lL; Gibco BRL, Grandland, NY, USA) was then
added to the D-mix, vortexed for 15 seconds, and 10
lL of the D-mix mixture was transferred to a 96-well
microtiter genotyping tray with dried primers in each
reaction well. A Perkin-Elmer 9600 thermocycler
(Perkin-Elmer-Cetus, Norwalk, CT, USA) was used to
amplify the promoter regions by PCR. Samples were sub-
jected to 10 cycles at 96◦C for 10 seconds, and 63◦C for
60 seconds, followed by 20 cycles at 96◦C for 10 seconds,
annealing at a temperature of 59◦C for 50 seconds and
72◦C for 30 seconds. After the PCR process, the am-
plified DNA fragments were separated by agarose gel
electrophoresis and visualized by staining with ethidium
bromide and exposure to ultraviolet light in a UV tran-
silluminator. Interpretation of PCR-SSP results is based
on the presence or absence of a specific amplified DNA
fragment. An internal control primer pair was included
in every PCR reaction to exclude nonspecific amplifica-
tion affected by several factors, such as pipetting errors,
poor DNA quality, presence of inhibitors, and others. A
positive reaction for a specific cytokine allele or allele
group is visualized on the gel as an amplified DNA frag-
ment between the internal control product band and the
unincorporated primer band.
Phenotype assignments
Cytokine production phenotype was assigned based on
the genetic information. These production phenotypes
for IL-6, TNF-a, and IL-10 were based on previously
published in vitro transfection studies using constructs of
the relevant alleles, studies on whole blood, and PBMC
cultures stimulated with endotoxin, and in vivo studies
measuring plasma levels of the relevant cytokines [12].
Specifically, high-, intermediate-, or low-producer pheno-
types were assigned to IL-6, TNF-a, and IL-10 as follows:
IL-6, position –174: high-producer genotype (G/G and
G/C) or low-producer genotype (C/C); TNF-a, position
–308: high-producer genotype (A/A and G/A) and low-
producer genotype (G/G); and IL-10, position −1082:
high-producer genotype (G/G), intermediate-producer
genotype (G/A), and low-producer genotype (A/A).
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Table 2. Baseline characteristics (183 chronic HD patients)
Age years 62 ± 12
Male gender % 46%
Race %
Caucasian 44%
African American 56%
Diabetes mellitus % 40%
Dialysis vintage years 3.7 ± 4.4
Karnofsky index 80 (40–100)
ICED score % 2 (1–3)
Body mass index kg/m2 24.6 ± 5.1
Equilibrated Kt/V 1.4 ± 0.2
Protein catabolic ratio g/kg/day 1.0 ± 0.2
Serum albumin g/dL 3.6 ± 0.4
Hematocrit % 33.4 ± 5.1
Results expressed as mean ± SD, or number (%) or median (range), as appli-
cable.
Plasma IL-6 and PBMC cytokine production
Plasma IL-6 was measured by commercial, high-
sensitivity sandwich enzyme-linked immunosorbent as-
say (ELISA) kits (QuantikineTM Human IL-6 HS
ELISA; R&D Systems, Minneapolis, MN, USA). The
minimum detection limit for this assay was 0.039 pg/mL.
To measure stimulated TNF-a and IL-10 production,
0.5 mL suspensions of PBMC (2.5 × 106 cells) were in-
cubated with 0.5 mL of RPMI containing 20 ng/mL en-
dotoxin (ET) (Escherichia coli, serotype 055:B5; Sigma,
St. Louis, MO, USA) (final ET concentration 10 ng/mL)
at 37◦C with 5% CO2. At the end of 24 hours, the cell sus-
pensions were subjected to three freeze-thaw (−70◦C)
cycles for measurement of total TNF-a and IL-10 pro-
duction (cell-associated and secreted). TNF-a and IL-10
were measured using commercial quantitative sandwich
enzyme immunoassays (R&D Systems). The detection
limits for IL-10 and TNF-a were 4.4 pg/mL and 1.5 pg/mL,
respectively. All samples were tested in duplicate and in
appropriate dilutions, and all samples for a given assay
were tested simultaneously.
Statistical analysis
Analysis was performed using the Statistical Analy-
sis Software (SAS), version 8.2 (Cary, NC). The inde-
pendent sample t test and one-way analysis of variance
(ANOVA) with the Bonferroni correction for multiple
comparisons were used to compare differences between
groups, and the chi-square test was used for differences
in proportions and linear trends. Univariate and multi-
variate analyses were performed to test the effect of dif-
ferent cytokine genotypes, genotype combinations, and
other relevant variables on comorbidity (ICED score),
functional status (Karnofsky Index), serum albumin, and
nutritional markers (body mass index, anthropometric
measurements, and nPCR). IDS scores for diabetes were
expressed independently, and the ICED scores used in
analysis did not include the IDS scores for diabetes. All
multivariate models were adjusted for age, gender, race,
dialysis vintage, and diabetes. We tested for interactions
between the different cytokine genotypes and other vari-
ables in the model.
Ordinary least squares (OLS) regression model was
fitted to albumin and body mass index (BMI). The dis-
tribution of serum albumin was fairly normal. The dis-
tribution of BMI was skewed to the right; hence, it was
log-transformed for purposes of analyses.
Proportional odds (PO) models were used to analyze
ordinal response data with more than two levels, namely
the ICED score and the KI (PO models fit the cumula-
tive logits by performing ordered logistic regression). The
outcomes were higher or less favorable ICED score, and
lower or less favorable Karnofsky score. We checked for
the ordinality assumption for each covariate by plots of
means for each level of ICED score and KI and found
that this assumption was met for all variables that were
significant in the univariate analysis. The proportionality
assumption was checked using a graphical approach de-
veloped by Petterson and Harrell [13] using residuals for
each covariate. Univariate, as well as age, race, gender,
dialysis vintage, and diabetes adjusted multivariate PO
models were performed for all genotypes and genotype
combinations, with ICED and Karnofsky scores as the
outcome variables, as outlined above.
The effect of individual cytokine genotypes and geno-
type combinations on the selected secondary outcomes
of the HEMO Study were explored using Cox propor-
tional hazards regression. Models were adjusted for the
dialysis dose and flux grouping assignment from the ran-
domization of the parent study, in addition to baseline
covariates.
P values < 0.05 were considered significant.
RESULTS
Demographic characteristics and genotype frequencies
in the cohort
Demographic characteristics and baseline laboratory
data are provided in Table 2. Gel interpretation, and
therefore, allele identification for IL-6 and IL-10 could
not be reliably performed for five and three patients, re-
spectively. Figure 1 presents the frequencies of the differ-
ent cytokine genotypes in the cohort, and Table 3 shows
the frequency distribution of individual genotypes and
alleles by race.
Relationship between individual cytokine genotypes
and ICED score
A higher proportion of patients with the IL-6 high-
producer genotype had ICED scores of 2 and 3 (higher
comorbidity) compared with those with the IL-6 low-
producer genotype (P = 0.03). Similarly, a higher propor-
tion of patients with the TNF-a high-producer genotypes
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Fig. 1. Distribution of cytokine genotypes by phenotypic characteris-
tics in the cohort (low, intermediate, and high producers).
Table 3. Frequency distribution of individual genotypes and alleles
stratified by race
Genotype and allele N African American Caucasian P value
IL-6: −174 178
C/C 3 (4%) 9 (9%)
G/C 15 (19%) 36 (36%) <0.01a
G/G 61 (77%) 54 (55%)
G:C 87:13 73:27 <0.01a
TNF-a: −308 183
A/A 1 (1%) –
G/A 23 (27%) 21 (21%) 0.31
G/G 58 (72%) 80 (80%)
G:A 85:15 90:10 0.27
IL-10: −1082 180
A/A 31 (39%) 29 (29%)
A/G 38 (48%) 52 (51%) 0.23
G/G 10 (13%) 20 (20%)
G:A 37:63 46:54 0.11
achi-square test.
Table 4. Relationship of cytokine levels to genotype
Production/plasma
Cytokine Genotype N levels pg/mL P value
IL-6 −174 C/C 12 12.2 ± 5.1 0.05a
−174 G/G, G/C 166 15.01 ± 17.4
TNF-a −308 G/G 134 998.8 ± 1156.2 0.56
−308 G/A, A/A 43 1131.1 ± 1616.2
IL-10 −1082 A/A 58 344.8 ± 356.3 0.01b
−1082 G/A 88 391.0 ± 440.5
−1082 G/G 29 627.4 ± 506.2
Data are displayed as mean (± SD).
aLevene’s test for unequal variances.
bKruskall-Wallis test.
had scores of 2 and 3 as compared with the TNF-a low-
producer genotype, although this did not reach statistical
significance (P = 0.06). There was no significant differ-
ence in ICED score distribution between the different
IL-10 genotypes (P = 0.35) (Table 5).
On both univariate and multivariate analysis (Table 6),
the presence of the IL-6 high-producer genotype was as-
sociated with increased odds (over four-fold) of higher
ICED scores compared to the IL-6 low-producer geno-
type. The multivariate model was adjusted for age,
gender, race, diabetes, and duration on HD; of these co-
variates, only diabetes (OR = 3.2, 95%CI, 1.7 to 5.9, P =
<0.001) was significant in the model. Because the distri-
bution of individual IL-6 genotypes and alleles appeared
to differ by race, a stratified analysis was undertaken.
The presence of the IL-6 high-producer genotype in Cau-
casians was still associated with a four-fold higher risk of
higher ICED scores (P = 0.05), but this did not reach
statistical significance after adjustment for covariates
(P = 0.06). The analysis in African Americans was lim-
ited by the extremely small number of patients with the
IL-6 low-producer genotype (C/C) (N = 3).
The presence of the TNF-a high-producer genotype
was associated with a two-fold increased odds of higher
ICED scores compared with the TNF-a low-producer
genotype (95% CI, 1.03 to 3.88, P = 0.04), after ad-
justment for the above covariates. Here again, diabetes
was the only covariate with a significant association with
higher ICED scores. The association of IL-10 genotypes
with ICED scores did not reach statistical significance.
Relationship between individual cytokine genotypes
and Karnofsky Index
Patients with the IL-6 high-producer genotype or the
TNF-a high-producer genotype had a lower KI (more
functional impairment) compared with those with the
respective low-producer genotypes. In contrast, patients
with the IL-10 high- and intermediate-producer geno-
types had higher KI compared with those with the IL-10
low-producer genotype (Table 5). The univariate analysis
revealed significant relationships between KI and IL-6,
TNF-a, and IL-10 genotypes. On multivariate analysis,
after adjustment for age, gender, race, duration on dial-
ysis, and diabetes, the odds of having a lower KI (more
functional impairment) were higher in patients with the
IL-6 and TNF-a high-producer genotypes compared with
their respective low-producer genotypes (OR = 4.9, P =
0.04, and OR = 2.2, P = 0.02, respectively) (Table 6).
The relationship between IL-10 genotype and KI did not
reach significance after adjustment for covariates. Of the
covariates, older age and diabetes were significantly asso-
ciated with a lower KI; univariate relationships showed
that each increasing year of age was associated with a
2% higher likelihood of a lower KI (OR = 1.02, 95% CI,
1.0 to 1.05, P = 0.05), and the presence of diabetes was
associated with a 2.6-fold higher likelihood (OR = 2.55,
95% CI, 1.45 to 4.47, P = 0.001). These relationships were
similar in the multivariate analysis.
As with ICED, a race-stratified analysis was carried out
to evaluate the relationship between IL-6 genotypes and
KI. The analysis had to be limited to Caucasians, however,
because there were very few African Americans with the
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Table 5. Relationship between genotypes and outcome variables: ICED Score, Karnofsky Index, and serum albumin
Outcome parameter TNF-a genotypes IL-6 genotypes IL-10 genotypes
Low producer High producer Low producer High producer Low producer High producer
ICED score N (%) N (%) N (%) N (%) N (%) N (%)
1 51 (38%) 8 (19%) 8 (67%) 50 (31%) 15 (25%) 42 (36%)
2 40 (30%) 18 (42%) 3 (25%) 55 (34%) 21 (36%) 37 (32%)
3 43 (32%) 17 (40%) 1 (8%) 57 (35%) 23 (39%) 37 (32%)
P value 0.06 0.03 0.35
Mean ± SD Mean ± SD Mean ± SD
Karnofsky Index 81 ± 16 74 ± 18 89 ± 14 78 ± 17 75 ± 18 81 ± 16
P value 0.02 0.03 0.02
Serum albumin g/dL 3.7 ± 0.4 3.5 ± 0.3 3.6 ± 0.4 3.6 ± 0.4 3.6 ± 0.4 3.6 ± 0.4
P value 0.05 0.92 0.79
Mean ± SD Mean ± SD Mean ± SD
BMI kg/m2 25.0 ± 5.0 23.6 ± 5.1 24.9 ± 4.2 24.6 ± 5.1 24.1 ± 4.9 24.9 ± 5.9
P value 0.14 0.84 0.27
Mean ± SD Mean ± SD Mean ± SD
nPCR g/kg/d 1.0 ± 0.2 1.0 ± 0.2 0.9 ± 0.2 1.0 ± 0.2 1.0 ± 0.3 1.0 ± 0.2
P value 0.63 0.25 0.82
BMI, body mass index; nPCR, normalized protein catabolic rate. Data were available for 178 patients for ICED score, 180 patients for Karnofsky Index, 181 patients
for serum albumin, and 178 patients for nPCR.
IL-6 low-producer genotype (N = 3). Caucasian patients
with the IL-6 high-producer genotype had lower KI,
but the association did not reach statistical significance
(OR = 8.14, 95% CI, 0.89 to 74.3, P = 0.06).
Relationship between individual cytokine genotypes
and serum albumin
Patients with the TNF-a high-producer genotype had
lower serum albumin compared with those with the low-
producer genotype. There were no significant differences
in serum albumin among the various IL-6 and IL-10
genotypes.
On univariate analysis, patients with the TNF-a high-
producer genotype were estimated to have mean serum
albumin levels 0.13 g/dL lower than patients with the
TNF-a low-producer genotype (Table 5). This relation-
ship was seen even after adjustment for covariates in the
multivariate model. Males had adjusted serum albumin
levels 0.23 g/dL higher than females; there was no asso-
ciation between serum albumin and the other covariates.
Relationship between individual cytokine genotypes
and other nutritional indices
There were no significant associations between indi-
vidual TNF-a, IL-6, and IL-10 genotypes and BMI, an-
thropometric measurements, or nPCR. Serum albumin
showed a poor but significant correlation with nPCR
(r = 0.17, P = 0.01), but not with BMI or other anthro-
pometric measurements.
Association between cytokine genotype combinations
and comorbidity, functional, and nutritional indices
Stratification by cytokine genotype combinations
yielded three categories for the IL-6/TNF-a and IL-6/IL-
10 combinations, and four categories for the TNF-a/IL-
10 combination (Table 6). There were no patients with
the low-IL-6/high-TNF-a producer genotype combina-
tion, and only two patients with the low-IL-6/low-IL-10
producer genotype combination who were not included
in the analysis. This stratified analysis therefore allowed
comparisons of the effect of genotype combinations, as
well as the effect of each cytokine independent of the
other.
Cytokine genotype combinations and ICED score
IL-6/TNF-a genotype combinations. Figure 2A shows
that a higher proportion of patients with the high-
IL-6/high-TNF-a producer genotype combination had
ICED scores of 2 and 3 (higher comorbidity) compared
with patients with the high-IL-6/low-TNF-a and low-IL-
6/low-TNF-a producer genotype combination. (P = 0.01,
Mantel-Hansel v 2 for linear trend). On multivariate anal-
ysis, after adjustment for age, gender, race, and dialysis
vintage, the odds of a higher ICED score was greater with
the high-IL-6/high-TNF-a and the high-IL-6/low-TNF-a
genotype combination relative to patients with the low-
IL-6/low-TNF-a genotype combination (OR of 8.3 and
4.2, respectively) (Table 7). The difference in OR between
the high-IL-6/high-TNF-a and high-IL-6/low-TNF-a pro-
ducer genotype combination was also significant (P =
0.05, Wald v 2 test), suggesting that the risk conferred by
one cytokine genotype was influenced by the other.
IL-6/IL-10 genotype combination. A lower propor-
tion of patients with the low-IL-6/high-IL-10 producer
genotype combination had ICED scores of 2 and 3 com-
pared with those with the high-IL-6/high-IL-10 producer
genotype combination, which was, in turn, lower than
among patients with the high-IL-6/low-IL-10 genotype
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Table 6. Relationship between cytokine genotypes and outcome variables (ICED Score, Karnofsky Index, and serum albumin)
Univariate analysis Multivariate analysis
Outcome OR 95% CI for OR P value OR 95% CI for OR P value
Higher ICED score on an ordinal scale of 1 to 3a
IL-6 high producer (GC or GG) vs. low producer (CC) 4.66 1.37, 15.89 0.01 4.87 1.35, 17.58 0.02
TNF-a high producer (GA or AA) vs. low producer (GG) 1.79 0.94, 3.38 0.08 2.00 1.03, 3.88 0.04
IL-10 high or intermediate producer (GG or GA) vs. low producer (AA) 0.67 0.38, 0.83 0.18 0.70 0.38, 1.26 0.23
Lower Karnofsky Index on an ordinal scale of 50 to 100a
IL-6 high producer (GC or GG) vs. low producer (CC) 5.69 1.24, 26.05 0.03 4.91 1.05, 22.95 0.04
TNF-a high producer (GA or AA) vs. low producer (GG) 2.10 1.12, 3.93 0.02 2.16 1.13, 4.12 0.02
IL-10 high or intermediate producer (GG or GA) vs. low producer (AA) 0.56 0.32, 1.01 0.05 0.64 0.35, 1.15 0.14
Serum albuminb PE 95% CI for PE P value PE 95% CI for PE P value
IL-6 high producer (GC or GG) vs. low producer (CC) 0.01 −0.22, 0.24 0.92 0.06 −0.16, 0.28 0.60
TNF-a high producer (GA or AA) vs. low producer (GG) −0.13 −0.26, 0.002 0.05 −0.14 −0.27, −0.01 0.03
IL-10 high or intermediate producer (GG or GA) vs. low producer (AA) 0.02 −0.11, 0.14 0.79 −0.01 −0.13, 0.11 0.90
aProportional odds models: ICED score levels 1, 2, and 3. Karnofsky Index levels ≤50, 60–70, 80, and 90–100. Each cytokine genotype listed above represents a
separate model adjusted for the following covariates, age, gender, race, diabetes mellitus, and duration on HD.
bMultiple linear regression model. Each cytokine genotype listed above represents a separate model adjusted for the following covariates, age, gender, race, diabetes
mellitus, and duration on HD. Parameter estimate (PE, the slope or b) identifies the change in serum albumin attributable to the designated change in the independent
variable.
combinations (P = 0.03, Mantel-Hansel v 2 test for linear
trend) (Fig. 2B). In the multivariate model, the odds of a
higher ICED score was greater among patients with the
high-IL-6/high-IL-10 and high-IL-6/low-IL-10 producer
genotype combinations relative to those with the low-
IL-6/high-IL-10 producer genotype combination (OR of
3.68 and 4.80, respectively), but only the comparison
between the two polar combinations, the high-IL-6/high-
IL-10 and low-IL-6/high-IL-10 producer genotype com-
binations, reached significance (Table 7).
TNF-a/IL-10 genotype combinations. The TNF-a/IL-
10 genotype combinations showed a similar linear trend
in the proportion of patients with higher ICED scores
ranging from the lowest in those with the low-TNF-
a/high-IL-10 to the highest in those with the high-
TNF-a/low-IL-10 producer genotype combination, on
univariate analysis (Fig. 2C). On multivariate analysis,
only the comparison between the two polar combinations,
the low-TNF-a/high-IL-10 and the high-TNF-a/low-IL-
10 producer genotypes, reached statistical significance af-
ter adjustment for other covariates.
Cytokine genotype combinations and the
Karnofsky Index
IL-6/TNF-a genotype combinations. The mean KI was
significantly different among the three IL-6/TNF-a geno-
type combinations, as seen in Figure 3A (P = 0.02). Pa-
tients with the high-IL-6/high-TNF-a producer genotype
combination had the lowest, and those with the low-
IL-6/low-TNF-a genotype combination the highest KI
(significant by Bonferroni correction, P =0.02; other pair-
wise comparisons not significant). After adjustment for
age, gender, race, and diabetes, patients with the high-
IL-6/high-TNF-a producer genotype combination had
significantly higher odds of having a low KI, relative
to those who carried the low-IL-6/low-TNF-a producer
genotype combination (Table 7). Although the difference
in OR between the high-IL-6/low-TNF-a genotype com-
bination and the low-IL-6/low-TNF-a producer genotype
combination did not reach significance (P = 0.07), the
comparison between the high-IL-6/high-TNF-a genotype
combination and the high-IL-6/low-TNF-a genotype
combination did (P = 0.05, Wald v 2 test), suggesting that
the risk conferred by one cytokine genotype was influ-
enced by the other (Table 7).
IL-6/IL-10 genotype combination. The mean KI was
significantly different among the three IL-6/IL-10 geno-
type combinations, as seen in Figure 3B (P = 0.008).
Patients with the high-IL-6/low-IL-10 producer geno-
type combination had the lowest KI, and those with the
low-IL-6/high-IL-10 genotype combination the highest
KI. Pairwise comparisons (with the Bonferroni correc-
tion) showed that patients with the high-IL-6/low-IL-10
producer genotype combination had a KI that was sig-
nificantly lower than patients with either the high-IL-
6/high-IL-10 producer genotype combination (P = 0.05)
or the low-IL-6/high-IL-10 producer genotype combina-
tion (P = 0.03), but the difference between the high-IL-
6/high-IL-10 and low-IL-6/high-IL-10 producer genotype
combinations was not significant (P = 0.41). Multivari-
ate analysis demonstrated a difference between the polar
combinations, the high-IL-6/low-IL-10 producer geno-
type combinations being associated with higher odds of a
low KI compared with the low-IL-6/high-IL-10 producer
genotype combination (OR of 5.99, Table 7). The differ-
ence in odds for a lower KI between the high-IL-6/low-
IL-10 compared with the high-IL-6/high-IL-10 producer
genotype combinations did not reach statistical signifi-
cance (P = 0.08).
TNF-a/IL-10 genotype combinations. TNF-a/IL-10
genotype combinations again indicated that patients with
the low-TNF-a/high-IL-10 genotype combination had
the highest KI, with a progressive decrease in KI across
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Fig. 2. Relationship between cytokine genotype combinations (by
phenotypic characteristics) and Index of Coexistent Diseases (ICED)
scores in the cohort. TNF-a/IL-6 (A), IL-6/IL-10 (B), and TNF-a/IL-10
(C) combinations. P values were derived from Mantel-Hansel v 2 test
for linear trend.
the low-TNF-a/low-IL-10, and high-TNF-a/high-IL-10
producer genotype combination, to the lowest score in
patients with high-TNF-a/low-IL-10 producer genotype
combination (P = 0.01) (Fig. 3C). Pairwise comparisons
(applying the Bonferroni correction) showed a signif-
icant difference between the two polar combinations
(P = 0.05); other pairwise comparisons did not reach
significance. On multivariate analysis, compared with pa-
tients with the low-TNF-a/high-IL-10 producer genotype
combination, patients with the high-TNF-a/high-IL-10
genotype combination or the high-TNF-a/low-IL-10 pro-
ducer genotype combination, showed significantly higher
odds of having a lower KI (P = 0.03 and 0.01, respec-
tively) (Table 7). The differences in odds between the
low-TNF-a/low-IL-10, high-TNF-a/high-IL-10 and high-
TNF-a/low-IL-10 producer genotype combinations was
not significant.
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Fig. 3. Relationship between combinations of cytokine genotypes (by
phenotypic characteristics) and Karnofsky Index in the cohort. TNF-
a/IL-6 (A), IL-6/IL-10 (B), and TNF-a/IL-10 (C) combinations. P values
were derived from one-way analysis of variance (ANOVA).
Cytokine genotype combinations and nutritional indices
TNF-a/IL-10 genotype combinations. Patients with
the high-TNF-a/low-IL-10 producer genotype combina-
tion had a significantly lower BMI compared with those
with the lowTNF-a/high-IL-10 producer genotype com-
bination (22.4 ± 4.4 kg/m2 vs. 25.3 ± 5.0 kg/m2, P =
0.05). Multivariate analysis for BMI (log-transformed
to normalize its distribution), adjusted for age, gender,
race, dialysis vintage, and diabetes showed a 12% lower
BMI (95% CI, 2 to 22, P = 0.02) in patients with the
high-TNF-a/low-IL-10 producer genotype combination
compared with patients with the low-TNF-a/high-IL-10
combination.
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Table 7. Multivariate analysis of the relationship between cytokine genotype combinations and ICED and Karnofsky scores
Higher (less favorable) Higher (more favorable)
ICED Scorea Karnofsky Indexa
Genotype combinations OR 95% CI P OR 95% CI P
Reference: Low IL-6 + low TNF-a producerb
High IL-6 + low TNF-a producer 4.20 1.15, 15.38 0.03 4.17 0.88, 19.70 0.07
High IL-6 + high TNF-a producer 8.32 2.08, 33.38 0.003 8.13 1.61, 41.00 0.01
Reference: Low IL-6 + high IL-10 producerb
High IL-6 + high IL-10 producer 3.68 1.00, 14.07 0.06 3.49 0.72, 16.94 0.12
High IL-6 + low IL-10 producer 4.80 1.19, 19.34 0.03 5.99 1.19, 30.10 0.03
Reference: Low TNF-a + high IL-10 producer
Low TNF-a + low IL-10 producer 1.40 0.71, 2.78 0.33 1.77 0.88, 3.54 0.11
High TNF-a + high IL-10 producer 1.96 0.87, 4.41 0.10 2.42 1.08, 5.43 0.03
High TNF-a + low IL-10 producer 3.84 1.17, 12.59 0.03 3.87 1.31, 11.41 0.01
Odds ratios (OR) are shown for individual genotype combinations, in comparison to the reference category with an OR of 1.0.
aProportional odds model adjusted for age, gender, race, dialysis vintage, diabetes.
bThere were no patients in the low IL-6 and high TNF-a genotype combination category. The low IL-6 and low IL-10 genotype combination contained only 2 patients
who were excluded from the analysis.
There was no significant association between cytokine
genotype combinations and other nutritional indices, in-
cluding anthropometric measurements, nPCR, or serum
albumin levels.
Relationship between cytokine levels and genotypes
Plasma IL-6 levels and results of ex vivo endotoxin-
stimulated TNF-a and IL-10 production by PBMC are
shown in Table 4. Plasma IL-6 levels were significantly
higher in patients with the high-IL-6 producer geno-
types (G/G and G/C) compared with those with the
low-producer genotype (C/C) (15.01 ± 17.4 vs. 12.2 ±
5.1, P = 0.05). Similarly, there was a significant differ-
ence in endotoxin-stimulated IL-10 production by PBMC
between patients with the high- (G/G), intermediate-
(G/A), and low- (A/A) IL-10 producer genotypes (P =
0.01, Kruskal-Wallis test). Mean PBMC IL-10 produc-
tion was highest among patients with the high-producer
G/G genotype. Pair-wise comparisons showed that the
differences between –1082 G/G and A/A, and –1082 G/G
and –1082 G/A were significant (P = 0.01 and P = 0.03,
respectively, with Bonferroni correction), although the
difference between –1082 G/A and A/A did not reach
significance. Although endotoxin-stimulated TNF-a pro-
duction was higher among patients with the high-
compared with the low-TNF-a producer genotype, this
difference did not reach statistical significance.
Association with clinical outcomes
Follow-up information on outcomes was available in
175 patients who were randomized to high or standard
dialysis dose, and to high- or low-flux dialyzer limbs of
the HEMO Study. The median duration of follow-up was
824 days (1 to 2376 days). A total of 101 patients (58%)
died during follow-up, 102 (58%) had a composite event
of albumin decline or death from any cause, 101 (50%)
had a composite event of first cardiac hospitalization or
cardiac death, and 44 (25%) had a cardiovascular cause
for death. Overall actuarial survival in the cohort was
89% at one year, 67% at two years, and 51% at three
years. There were no demonstrable associations between
individual genotypes or genotype combinations and the
above primary and secondary outcomes defined in the
HEMO Study.
DISCUSSION
There is considerable evidence for a cytokine-
orchestrated chronic inflammatory response in patients
on long-term HD. Indeed, several studies have shown
that plasma levels of proinflammatory cytokines such as
IL-1 and TNF-a are elevated among patients on HD [14].
In addition, some, but not all studies have reported a fur-
ther increase in circulating levels of cytokines during the
course of an HD treatment [15, 16]. These cytokines have
been incriminated in the short- and long-term morbidity
experienced by HD patients. Proinflammatory cytokines
such as TNF-a and IL-6 may suppress appetite [17]
and induce catabolism [18], leading to a wasting illness
that may be indistinguishable from malnutrition. Bologa
et al found a significant correlation between plasma TNF-
a and IL-6, and the degree of hypoalbuminemia and
dyslipoproteinemia among HD patients. This study also
found that plasma IL-6 level was a predictor of mor-
tality among these patients [2]. Likewise, Kimmel et al
[19] found that elevated plasma levels of TNF-a and IL-
6 among HD patients were significantly associated with
an increased relative risk of death. We have observed
that higher endotoxin-stimulated cytokine synthesis by
PBMC predicted morbidity from cardiovascular events
[20]. There is, however, considerable interindividual vari-
ability in cytokine secretion patterns in response to stim-
uli. This is determined, at least in part, by polymorphisms
within the promoter region of these cytokines, and may
have a significant influence on individual susceptibility to
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cytokine-induced chronic inflammation and its attendant
morbidity.
The results of this study demonstrate an important
association between single nucleotide polymorphisms
within the promoter region of cytokine genes, and in-
dices of comorbidity and function and serum albumin
in a cohort of ESRD patients on long-term HD. These
associations remained significant despite adjustment for
age and diabetes, both of which are established risk fac-
tors for poor outcomes. In the present study, a higher
proportion of patients with the IL-6 high-producer geno-
types had ICED scores of 2 or 3 (moderate to severe
comorbidity) and lower Karnofsky scores than patients
with the IL-6 low-producer genotype. After adjustment
for other covariates, IL-6 genotypes retained a strong as-
sociation with comorbidity and functionality. The multi-
variate model indicated that the odds of a higher ICED
score was nearly five-fold higher in patients with the IL-
6 high-producer genotype compared with patients with
the IL-6 low-producer genotype. Despite the low preva-
lence of the IL-6 low-producer genotype in the cohort,
we believe these results are sufficiently robust to indicate
a significant association between IL-6 genotypes and co-
morbidity and functional status in HD patients.
The –174 G→C promoter region polymorphism of the
IL-6 gene has been shown to be functionally relevant.
Transient transfection experiments using reporter gene
constructs containing either allele indicate that the C
allele results in suppression of IL-6 transcription in re-
sponse to endotoxin or IL-1 in HeLa cells [21]. The pres-
ence of the C allele has also been associated with lower
serum levels of IL-6 in healthy subjects, supporting the in
vitro observation of reduced promoter strength [21]. In
contrast, Fernandez-Real et al [22] have recently shown
that carriers of the G allele at position –174 demonstrated
higher plasma IL-6 levels and were more prone to lipid
abnormalities. Other investigators have also shown that
among patients with coronary artery disease, the G/G
genotype is associated with higher plasma IL-6 levels and
with longer hospitalization than the presence of the C
allele [23]. In the present study, we were able to con-
firm the association of the G/G and G/C genotypes with
higher plasma IL-6 levels relative to patients with the C/C
genotype.
The –308 G→A TNF-a polymorphism also showed
a significant association with comorbidity, functionality,
and serum albumin level. The presence of the –308A al-
lele (also referred to as the TNF2 allele), or the TNF-a
high-producer genotype (G/A or A/A) was associated
with higher comorbidity, lower Karnofsky scores, and
lower serum albumin concentrations than patients with
the wild-type TNF-a low-producer genotype (G/G). On
multivariate analysis, TNF-a genotypes retained a strong
association with ICED scores, Karnofsky Index, and
serum albumin levels after adjustment for other covari-
ates. As patients with a low serum albumin were ex-
cluded from enrollment into the HEMO Study, the effect
noted in this study on serum albumin was particularly
significant.
The –308A allele has been associated with high pro-
moter activity [6] and has been found to correlate with
enhanced spontaneous and stimulated TNF-a production
both in vitro and in vivo [12]. Furthermore, the TNF2
polymorphism has been associated with increased mor-
bidity and mortality of severe forms of cerebral malaria
[24], fulminans purpura [25], and mucocutaneous leish-
maniasis [26]. Other investigators have shown that the
TNF2 allele is strongly associated with susceptibility to,
and mortality from, septic shock [27], and may also be
a susceptibility factor for systemic lupus erythematosus
(SLE) [28]. Although in the present study endotoxin-
stimulated TNF-a response of PBMC was higher among
patients with the high-producer G/A and A/A genotypes
compared with the G/G genotype, this difference did not
reach statistical significance.
Although IL-10 genotypes did not show an indepen-
dent association with comorbidity or serum albumin
concentrations, patients with the IL-10 high- or inter-
mediate-producer genotypes were more likely to have
higher Karnofsky scores than patients with the IL-10 low-
producer genotype. Twin studies and family studies have
suggested that ∼75% of the variation in IL-10 produc-
tion is genetically determined and appears to be con-
trolled at the transcriptional level [29]. In vitro studies
indicate that the –1082 G allele is associated with higher
IL-10 production and the A allele with lower IL-10 pro-
duction [30]. These observations have been confirmed by
transfection studies in U937 monocytic cell lines using
appropriate constructs [30]. Indeed, in the present study,
we observed higher endotoxin-stimulated IL-10 produc-
tion by PBMC among patients with the high-producer
G/G genotype compared with the other genotypes, con-
firming earlier observations. Autoimmune inflammatory
disorders such as SLE and rheumatoid arthritis, charac-
terized by high proinflammatory cytokine activity, appear
to be associated with an increased frequency of the low-
producer A allele [31]. It is therefore possible that ge-
netically determined lower production of IL-10 might
influence disease susceptibility and/or severity caused
by altered proinflammatory/anti-inflammatory cytokine
balance.
Patients with the combination of IL-10 high- or inter-
mediate-producer genotypes with the IL-6 low-producer
genotype, or the combination of IL-10 high- or interme-
diate-producer genotypes with the TNF-a low-producer
genotype had less comorbidity and higher Karnofsky
scores than patients with the opposite polar genotype
combinations. The combination of IL-10 high- or interme-
diate-producer genotypes with the TNF-a low-producer
genotype was also associated with significantly lower
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BMI. Given the strong regulatory influence of IL-10
on proinflammatory cytokine production, these observa-
tions indicate that synergistic or antagonistic effects may
come into play with genotype combinations, and these
may have a critical role in susceptibility to chronic in-
flammation and its sequelae in these patients. Indeed,
our results demonstrated a gradation of risk in the rela-
tionship between outcomes and genotype combinations
that would be expected to predispose to a proinflamma-
tory state, with a consistent linear trend demonstrable on
univariate analysis. Whereas on multivariate analysis, the
change in odds ratio attributable to each cytokine did not
consistently reach significance, this could be explained
by sample size, as well as a relatively lower prevalence of
certain genotypes in this cohort.
The HEMO Study population was a selected dialysis
population, weighted toward a relatively healthy preva-
lent cohort of HD patients, who could be considered
long-term survivors on dialysis. Although the restrictions
imposed by these selection criteria limit the generaliz-
ability of our results, demonstration of an association be-
tween cytokine genotypes and clinical indices lends added
significance to our observations. Comorbidity and func-
tional status were used as clinical end points, as they are
global indices of clinical status, and strong predictors of
survival, and therefore, may be more sensitive pheno-
types for the consequences of inflammatory processes.
This may also explain the lack of a detectable effect of
cytokine promoter polymorphisms on the HEMO Study
primary and secondary end points. Inflammatory pro-
cesses may be contributory in only a proportion of these
events, and this study probably had inadequate power to
detect this aspect of the relationship.
CONCLUSION
Results from this study indicate that single nucleotide
polymorphisms in the promoter region of the proinflam-
matory cytokines IL-6 and TNF-a, and the regulatory
monokine IL-10, are strongly associated with indices of
comorbidity and function, as well as serum albumin in
ESRD patients on long-term HD. Their influence on clin-
ical outcomes in patients with earlier stages of chronic
kidney disease will be the focus of further studies.
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